A rapid and cost-effective initial screening method for IDH mutation is mutation-specific immunohistochemistry, particularly for the common variant IDH1 p.R132H, which accounts for the vast majority of IDH mutations in GBM. This evidence concerns the gene IDH2 and glioblastoma.